Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Much awaited Phase III POLO trial data were presented at the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, and showed that Lynparza (olaparib) has a significant impact of progression of disease in certain pancreatic cancer patients. 3 June 2019
Biotechnology
Positive data at the annual meeting of the American Society of Clinical Oncology (ASCO) will help boost chances for Sanofi’s isatuximab in a looming head-to-head with Johnson & Johnson’s Darzalex (daratumumab). 3 June 2019
Biotechnology
Immunotherapy specialist Atara Biotherapeutics has presented clinical results relating to its biomarker research at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2019
Biotechnology
New baseline biomarker analyses and updated clinical study efficacy and safety results were shared in a presentation, titled "Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214, bempeg), at the 2019 American Society of Clinical Oncology (ASCO) meeting in Chicago. 3 June 2019
Biotechnology
Shares of Humanigen rose 8.7% to $1.24 by mid-morning today, after it revealed a clinical collaboration with Gilead Sciences’ subsidiary Kite to trial a combination of its flagship therapy in combination with one of the first CAR-T cell therapy to be approved by the US regulator. 31 May 2019
Biotechnology
Japanese drug major Astellas Pharma today announced that the US Food and Drug Administration approved a supplemental New Drug Application (sNDA) to update the US product labeling for Xospata (gilteritinib) to include final analysis data from the ADMIRAL trial. 31 May 2019
Biotechnology
Vertex Pharmaceuticals says it has selected the triple combination of the next-generation corrector VX-445 (elexacaftor), tezacaftor and ivacaftor to submit for potential global regulatory approvals for people ages 12 and older with cystic fibrosis (CF). 31 May 2019
Biotechnology
Atara Biotherapeutics, a US biotech specializing in T-cell immunotherapies for cancer, has named Pascal Touchon its new president, chief executive. 30 May 2019
Biotechnology
Inovio Pharmaceuticals regained much of the losses it suffered in the stock market on Wednesday, but the company’s share price was heading south again on Thursday. 30 May 2019
Biotechnology
California clinical-stage biotech Inhibrx has entered into an agreement with privately held Italian drugmaker Chiesi Farmaceutici, granting the latter an option to exclusively license, develop and commercialize INBRX-101 outside of the USA and Canada effective upon a $10 million equity investment in Inhibrx. 30 May 2019
Biotechnology
The National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Document for the use of Merck & Co’s Prevymis (letermovir/ID1153) in preventing cytomegalovirus (CMV) reactivation and disease in patients receiving an allogeneic stem cell transplant. 30 May 2019
Biotechnology
The share price of Canadian biopharma Zymeworks (TSX: ZYME) closed 4% up on Wednesday after the company received two separate validations of its approach. 30 May 2019
Biotechnology
USA-based private equity firm Ampersand Capital Partners announced plans to acquire Vibalogics GmbH, a German contract development and manufacturing organization (CDMO) focused on complex live biological products. 30 May 2019
Biotechnology
German pharma major Boehringer Ingelheim and Danish biotech Gubra has announced a second collaboration and license agreement for the development of new poly-agonist peptides to treat obesity. 29 May 2019
Biotechnology
Biomunex Pharmaceuticals, a privately-held French biotech focused on providing immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, has established a US subsidiary. 29 May 2019
Biotechnology
US biotech major Gilead Sciencestoday announced that Johanna Mercier will join the company as chief commercial officer, and will become a member of the company’s senior leadership team. 29 May 2019
Biotechnology
Juvenescence, a privately-held investment firm with a focus on increasing healthy human longevity, has announced the creation of a new biotech company to target the epigenetic underpinnings of neurodegeneration. 29 May 2019
Biotechnology
Phase III findings on BioMarin Pharmaceutical’s valoctocogene roxaparvovec were announced on Tuesday, leading the US biotech’s share value to fall by 5% by the close. 29 May 2019
Biotechnology
The US Food and Drug Administration has approved Revlimid (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL) following Priority Review designation. 29 May 2019
Biotechnology
US pharma major has signed a licensing agreement to acquire the exclusive worldwide rights for CNTX-0290 from privately-held US pain specialist Centrexion Therapeutics Corporation. 28 May 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze